Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
For better result, minimum character length is four(4)
WuXi PharmaTech has broken ground on a $100 million R&D...
Tigermed Consulting will add pre-clinical capability to...
WuXi PharmaTech has completed construction of a new...
Aslan Pharma of Singapore acquired global rights to...
WuXi PharmaTech formed a clinical biomarker partnership...
Crown Bioscience, a preclinical US-China CRO, closed a...
WuXi PharmaTech has begun high-potency active...
The $20 million China medical device JV formed by...
Steven Yang, PhD, the new COO of WuXi AppTech, may be the...
Luye Pharma priced its Hong Kong IPO at the top end of...
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China
